Patents Examined by Donald E. Adams
-
Patent number: 6767996Abstract: An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions encode a framework derived from a second different mammalian species. The or each constant domain of the antibody chain, if present, are also derived from the second mammalian species.Type: GrantFiled: May 17, 1993Date of Patent: July 27, 2004Assignee: Glaxo Wellcome Inc.Inventors: Scott David Gorman, Michael Ronald Clark, Stephen Paul Cobbold, Herman Waldmann
-
Patent number: 6265183Abstract: A method is disclosed for producing a modified eukaryotic cytoplasmic DNA virus by direct molecular cloning of a modified DNA molecule comprising a modified cytoplasmic DNA virus genome. The inventive method comprises the steps of (I) modifying under extracellular conditions a DNA molecule comprising a first cytoplasmic DNA virus genome to produce a modified DNA molecule comprising the modified cytoplasmic DNA virus genome; (II) introducing the modified DNA molecule into a first host cell which packages the modified DNA molecule into infectious virions; and (III) recovering from the host cell virions comprised of the modified viral genome. The host cell is infected with a helper virus which is expressed to package the modified viral genome into infectious virions. Examples of packaging a modified poxvirus genome by a helper poxvirus of the same or different genus are described.Type: GrantFiled: December 19, 1994Date of Patent: July 24, 2001Assignee: Baxter AktiengesellschaftInventors: Friedrich Dorner, Friedrich Scheiflinger, Falko Gunter Falkner, Michael Pfleiderer
-
Patent number: 6222024Abstract: Upon entry into a host cell, retroviruses direct the reverse transcription of the viral RNA genome and the establishment of an integrated proviral DNA. The retroviral integrase protein (IN) is responsible for the insertion of the viral DNA into host chromosomal targets. The IN catalyzes two specific biochemical reactions: (i) cleavage of the 3′termini of the viral DNA to produce 3′-OH ends, and (ii) joining of the two newly generated 3′-termini to the 5′-phosphates on each strand of the target sequence in a concerted strand-transfer reaction. The yeast two-hybrid system was used to identify a novel human gene product, herein designated integrase interactor 1 or INI-1, that binds tightly to the human immunodeficiency virus type 1 (HIV-1) integrase in vitro.Type: GrantFiled: May 24, 1994Date of Patent: April 24, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventors: Stephen P. Goff, Ganjam V. Kalpana
-
Patent number: 6165470Abstract: Utilization of albumin as a stable plasma transporter with a therapeutic function that is derived from a membrane receptor. The present invention is exemplified by the description of new therapeutic agents that can be used in the treatment of Acquired Immunodeficiency Syndrome: hybrid macromolecules composed of albumin derivatives coupled to derivatives of the CD4 receptor having a normal or a higher affinity for the HIV-1 virus.Type: GrantFiled: January 8, 1998Date of Patent: December 26, 2000Assignee: Rhone-PoulencInventors: Jerome Becquart, Reinhard Fleer, Philippe Hirel, David Klatzmann, Didier Landais, Jean-Fran.cedilla.ois Mayaux, Patrice Yeh
-
Patent number: 6162439Abstract: This invention is directed toward polypeptides derived from novel lentiviruses. A novel lentivirus, designated the human immunodeficiency virus type 2, was isolated from West African patients with acquired immune deficiency syndrome (AIDS). Several isolates were obtained and designated HIV-2.sub.ROD, HIV-2.sub.IRMO, and HIV-2.sub.EHO. A recombinant lambda phage library was constructed from HIV-2.sub.ROD -infected CEM genomic DNA. Overlapping molecular clones were obtained and the nucleotide sequence of the complete 9.5-kilobase (kb) HIV-2.sub.ROD genome ascertained. The genetic organization of HIV-2 is analogous to that of other retroviruses and consists of the 5'LTR-gag-pol-central region-env-nef-3'LTR. The central region also encodes for the regulatory proteins Tat and Rev, as well as the ancillary proteins Vif, Vpr, and Vpx. The proteins encoded by this proviral clone will provide novel immunologic, biochemic, and diagnostic reagents useful for the detection of HIV-2.Type: GrantFiled: June 6, 1995Date of Patent: December 19, 2000Assignee: Institut PasteurInventors: Marc Alizon, Luc Montagnier, Denise Guetard, Francois Clavel, Pierre Sonigo, Mireille Guyader
-
Patent number: 6103244Abstract: A method is disclosed for producing a modified eukaryotic cytoplasmic DNA virus by direct molecular cloning of a modified DNA molecule comprising a modified cytoplasmic DNA virus genome. The inventive method comprises the steps of (I) modifying under extracellular conditions a DNA molecule comprising a first cytoplasmic DNA virus genome to produce a modified DNA molecule comprising the modified cytoplasmic DNA virus genome; (II) introducing the modified DNA molecule into a first host cell which packages the modified DNA molecule into infectious virions; and (III) recovering from the host cell virions comprised of the modified viral genome. The host cell is infected with a helper virus which is expressed to package the modified viral genome into infectious virions. Examples of packaging a modified poxvirus genome by a helper poxvirus of the same or different genus are described.Type: GrantFiled: May 22, 1996Date of Patent: August 15, 2000Assignee: Immuno AG.Inventors: Friedrich Dorner, Friedrich Scheiflinger, Falko Gunter Falkner, Michael Pfleiderer
-
Patent number: 6096496Abstract: A combinatorial chemistry bead that includes an electromagnetic spectral emitter that radiates a distinct electromagnetic code for each bead that uniquely identifies each bead, a terminal apparatus for receiving the electromagnetic code from each bead, and a method for performing combinatorial synthesis using a bead that transmits a distinct electromagnetic code. The invention includes a large number of spectrally narrowed light emitting mechanisms for generating distinct optical codes.Type: GrantFiled: June 19, 1997Date of Patent: August 1, 2000Inventor: Robert D. Frankel
-
Patent number: 6077542Abstract: Substances that are solid at 25.degree. C. are obtained by dissolving sodium valproate in heated valproic acid and cooling the resultant solution. The resulting solid substances can easily be processed into solid pharmaceutical dosage forms.Type: GrantFiled: July 31, 1997Date of Patent: June 20, 2000Inventor: Bernard Charles Sherman
-
Patent number: 6074646Abstract: Recombinant human immunodeficiency virus antigens capable of immunologically identifying the presence of early anti-HIV antibodies are stably expressed in a number of cell lines. These antigens have several clinically important applications as non-hazardous tools in the detection of human immunodeficiency virus exposure/infection, and in screening methods for HIV infection in idiopathic chronic lymphopenia (ICL). These techniques are improved over existing immunologically based and PCR based detection methods, as they provide for the detection of infection/exposure in samples determined to be negative by conventional forms of these types of assays that do not detect anti-HIV gp160 antibodies that react to conformational epitopes of HIV. The invention finds particular application in the detection of human immunodeficiency virus exposure/infection in infants.Type: GrantFiled: October 9, 1996Date of Patent: June 13, 2000Assignee: Board of Regents, The University of Texas SystemInventors: Miles W. Cloyd, Keith M. Ramsey
-
Patent number: 6054005Abstract: Polymer structures having a laminated surface and enhanced physical properties that can be used for packaging, athletic gear (e.g., padding, water sport equipment), gaskets, and protective garments are described. The structures include a core of a relatively high density material and one or more layers laminated to the surfaces of the core material of relatively low density polymer foam. The structures can be stiff or flexible. The foam layers improve the softness of the surfaces of the core material.Type: GrantFiled: April 30, 1999Date of Patent: April 25, 2000Assignee: Sentinel Products Corp.Inventors: Robert F. Hurley, Matthew L. Kozma, John D. Bambara, Scott C. Smith, Richard Bambara
-
Patent number: 6054472Abstract: The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.Type: GrantFiled: April 2, 1997Date of Patent: April 25, 2000Assignee: Vertex Pharmaceuticals, IncorporatedInventors: David M. Armistead, Michael C. Badia, Guy W. Bemis, Randy S. Bethiel, Catharine A. Frank, Perry M. Novak, Steven M. Ronkin, Jeffrey O. Saunders
-
Patent number: 6034227Abstract: An isolated DNA sequence encoding a mammalian mast cell function-associated antigen (MAFA) is provided. A soluble derivative of the MAFA is obtained by culturing a host cell transformed by a recombinant expression vector comprising a sequence of said DNA encoding a form of soluble MAFA, and may be used for screening potential ligands of the MAFA. The ligands, alone or in combination with the MAFA, may be used in pharmaceutical compositions for the prevention of inflammatory and allergic reactions.Type: GrantFiled: October 8, 1996Date of Patent: March 7, 2000Assignee: Yeda Research and Development Co. Ltd.Inventors: Israel Pecht, Marcelo D. Guthmann, Michael Tal
-
Patent number: 6030917Abstract: The present invention relates, inter alia, to methodologies for the synthesis, screening and characterization of organometallic compounds and catalysts (e.g., homogeneous catalysts). The methods of the present invention provide for the combinatorial synthesis, screening and characterization of libraries of supported and unsupported organometallic compounds and catalysts (e.g., homogeneous catalysts). The methods of the present invention can be applied to the preparation and screening of large numbers of organometallic compounds which can be used not only as catalysts (e.g., homogeneous catalysts), but also as additives and therapeutic agents.Type: GrantFiled: July 22, 1997Date of Patent: February 29, 2000Assignee: Symyx Technologies, Inc.Inventors: W. Henry Weinberg, Eric McFarland, Isy Goldwasser, Thomas Boussie, Howard Turner, Johannes A. M. Van Beek, Vince Murphy, Timothy Powers
-
Patent number: 6027941Abstract: This invention includes methods for analyzing data generated by various solid-state NMR experiments, including rotational echo double resonance (REDOR), transferred echo double resonance (TEDOR), dipolar recoupling at the magic angle (DRAMA), dipolar recoupling with a windowless sequence (DRAWS), and melding of spin-locking and DRAMA (MELODRAMA). The methods are based alternately on a new analytical transform or the maximum entropy method and their multi-dimensional extensions. They permit simultaneous, multiple distance measurements of high accuracy and precision, even from nuclei with identical chemical shifts. By providing high quality easily obtained distance measurement from disordered solid state materials, this invention also improves drug discovery and design through fast determination of structures of pharmaceutical lead compounds, drug molecules, or their targets.Type: GrantFiled: May 15, 1996Date of Patent: February 22, 2000Assignee: CuraGen CorporationInventors: Thomas P. Jarvie, Joel S. Bader, Gregory T. Went
-
Patent number: 6015661Abstract: The present invention is directed toward immunologic- and nucleic acid-based methodologies for the detection of non-pathogenic human immunodeficiency virus type 1 (HIV-1) strains in the body fluids of HIV-infected individuals. A blood donor infected with HIV-1 and a cohort of six blood or blood product recipients infected from this donor were studied. These patients, who remained free of HIV-1-related disease and displayed stable and normal CD4 lymphocyte counts 10 to 14 years after infection, were termed long-term nonprogressors (LTNPs). The molecular characterization of HIV-1 sequences obtained from either virus isolates or patient peripheral blood mononuclear cells (PBMCs) of LTNPs identified similar deletions in the nef gene and in the region of overlap of nef and the U3 region of the long terminal repeat (LTR). These deletions corresponded to amino acids 166-206, or nucleotides 9281 to 9437, of the HIV-1.sub.NL43 nef/LTR region.Type: GrantFiled: June 7, 1995Date of Patent: January 18, 2000Assignee: The Macfarlane Burnet Centre for Medical Research LimitedInventors: Nicholas John Deacon, Dale Alan McPhee, Suzanne Crowe
-
Patent number: 5981286Abstract: The present invention concerns new hydrophilic metal complexes and their use as luminescent marker groups in immunoassays.Type: GrantFiled: January 16, 1997Date of Patent: November 9, 1999Assignee: Roche Diagnostics, GmbHInventors: Rupert Herrmann, Hans-Peter Josel, Gunter Pappert, Fritz Vogtle, Bruno Frommberger, Jorg Issberner
-
Patent number: 5972719Abstract: Combinatorial chemical libraries of Formula I ##STR1## and methods for their preparation are disclosed. The libraries allow one to screen large numbers of compounds for a desired biological activity with relative ease. The libraries may be tagged or untagged. In preferred libraries, Y is the residue of an N-acylated amino acid, a substituted 4-aminoproline or a substituted piperazinealkanoic acid. The use of the libraries to discover biologically active compounds is also disclosed.Type: GrantFiled: November 5, 1996Date of Patent: October 26, 1999Assignee: Pharmacopeia, Inc.Inventors: Roland Ellwood Dolle, III, Tao Guo, Theodore Otto Johnson, Jr., Hitesh K. Patel, Shiwei Tao, Zhen Min He
-
Patent number: 5965526Abstract: Cyclic pentapeptides are disclosed having the following formula (I) --Cyclo(-A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -A.sub.5 -)-- wherein A.sub.1, A.sub.2, A.sub.3, A.sub.4 and A.sub.5, are amino acid residues. The pentapeptide has amino acid residues in positions 1-2-3 to form a .gamma.-turn, and amino acid residues in positions 3-4-5-1 to form a .beta.-turn in combination with the .gamma.-turn. D-.alpha.-amino acid residues are selected for A.sub.1, A.sub.3, and A.sub.5 and L-.alpha.-amino acid residues are selected for A.sub.2 and A.sub.4. Compounds having .gamma.-turns and .beta.-turns can be synthesized, regardless of the kinds of amino acid residues, and it is possible to synthesize compounds in which desired amino acid residues are introduced into sites of .beta.-turn and .gamma.-turn based on their importance from the viewpoint of biological activity. The present invention is therefore available for design of compounds having biological activity.Type: GrantFiled: October 31, 1995Date of Patent: October 12, 1999Assignee: Takeda Chemical Industries, Inc.Inventors: Mitsuhiro Wakimasu, Hiroshi Inooka, Satoshi Endo, Takashi Kikuchi
-
Patent number: 5959093Abstract: The present invention provides the genes encoding the following BRV proteins: for group A, the VP4 and VP7 proteins of the Indiana (IND) strain, and the VP7 protein of the 2292B strain; for group B, the VP7 protein of the WD653 strain; for group C, the VP4 and VP7 proteins of the Shintoku strain. The genes are useful for producing nucleic acid probes which are complementary to the VP7 and VP4 genes. Such probes are useful for detecting the presence of group A,B, and C BRV in fecal samples from diarrheic calves and for determining the serotype of the BRV field isolates. The genes are also useful for producing partial length nucleic acid probes which are complementary to hypervariable regions of the VP4 and VP7 genes.The present invention also relates to partially purified VP2, VP4, VP6 and VP7 proteins of the IND strain and VP4 and VP7 of the 2292B strain, the partially purified VP7 protein of the WD653 strain, and partially purified VP2, VP4 and VP7 proteins of the Shintoku strain.Type: GrantFiled: June 28, 1996Date of Patent: September 28, 1999Assignee: The Ohio State University Research FoundationInventors: Linda J. Saif, Anil Parwani, Kyeong-Ok Chang, Wonyong Kim, Kathy Gadfield
-
Patent number: 5944510Abstract: A fluid injector for use with a burner having at least a pair of concentric tubes which conduct at least two different fluids via inner and outer passageways to a discharge tip. The passageways having different linear fluid velocity rates which causes the issuing discharge flow of the fluids to constrict causing mixing and combining of the fluids for introducing to a combustion chamber. Protection of the injector from thermal melting or burning is provided by location of the injector within the coils of a feed preheater constituting a heat exchanger.Type: GrantFiled: November 1, 1996Date of Patent: August 31, 1999Inventors: Leonard Greiner, David M. Moard